Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Scientists discover a hidden switch that shuts down inflammation | ScienceDaily (opens in a new tab)

sciencedaily.com · 2026-09-12

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

3 claims go further than the study. 2 other points were not covered by the paper.

  • 2 supported
  • 3 overstated
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

Three of seven claims overstate the study. Two of seven check out. Two claims the study doesn't address.

  • 2 supported
  • 3 overstated
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7OverstatedScientists have uncovered a natural braking system that helps the immune system switch off inflammation and prevent harmful immune cells from building up.View evidenceHide evidence

Why this verdict

The paper profile supports epoxy-oxylipins and sEH inhibition as modulators of pain resolution and monocyte dynamics, including a mechanism by which 12,13-EpOME blocks classical-to-intermediate monocyte transition. But the headline’s unhedged framing—an uncovered natural braking system that helps the immune system switch off inflammation and prevent harmful immune cells from building up—is broader and more causal than the abstract-level evidence. The paper reports no effect on heat, redness, or swelling, and the human data are from an acute experimental model in healthy volunteers. The headline therefore outruns both the evidence and the story body’s more cautious framing.

1

Study evidence

Epoxy‑oxylipins are detectable in peripheral blood at baseline and following intradermal UV‑killed E. coli challenge in healthy male volunteers.

“epoxy-oxylipins are present in blood of healthy, male volunteers at baseline and following intradermal injection of UV-killed Escherichia coli, an experimental model of acute resolving inflammation.”
2

Study evidence

Administration of the selective sEH inhibitor GSK2256294 specifically elevates circulating epoxy-oxylipins 12,13-EpOME and 14,15-EET.

“GSK2256294, a selective sEH inhibitor specifically elevates 12,13-EpOME and 14,15-EET.”
Claim 2 of 7OverstatedGiving the sEH inhibitor GSK2256294 before or after inflammation began increased epoxy-oxylipin levels, helped pain resolve more quickly, and sharply reduced intermediate monocytes in blood and tissue.View evidenceHide evidence

Why this verdict

The profile supports that GSK2256294 elevated 12,13-EpOME and 14,15-EET, hastened pain resolution, and significantly reduced circulating intermediate monocytes. However, the story adds details not supported at abstract depth—before-or-after timing, a 'sharp' magnitude, and a causal attribution to reductions in tissue intermediate monocytes. The profile reports fewer intermediate monocytes at the inflammatory site but does not specify the condition, timing, or whether GSK2256294 caused that site-level finding.

1

Study evidence

Administration of the selective sEH inhibitor GSK2256294 specifically elevates circulating epoxy-oxylipins 12,13-EpOME and 14,15-EET.

“GSK2256294, a selective sEH inhibitor specifically elevates 12,13-EpOME and 14,15-EET.”
2

Study evidence

GSK2256294 significantly reduces numbers of circulating intermediate monocytes that expand during experimentally induced inflammation.Significant reduction reported (no numeric magnitude provided in abstract)

“GSK2256294… significantly reduces numbers of circulating intermediate monocytes that expand during inflammation.”
Claim 3 of 7OverstatedThe article says one epoxy-oxylipin, 12,13-EpOME, appears to suppress p38 MAPK, and the team confirmed the mechanism in laboratory experiments and in volunteers who received a p38 blocker.View evidenceHide evidence

Why this verdict

The profile supports a mechanistic link in which 12,13-EpOME blocks classical-to-intermediate monocyte transition via a p38 MAPK-dependent mechanism, with similar effects when p38 MAPK is blocked in vitro and with losmapimod in vivo. But the story’s wording that 12,13-EpOME 'suppresses p38 MAPK' is more specific than the profile, which says the effect is p38-dependent and recapitulated by p38 blockade. 'Confirmed the mechanism' also overstates the abstract-level evidence, which lacks experimental details and quantitative results.

1

Study evidence

12,13-EpOME inhibits the transition of classical to intermediate monocytes in primary human monocyte culture; this effect is dependent on p38 MAPK signalling and is recapitulated by pharmacologic p38 MAPK blockade in vitro.

“12,13-EpOME blocks the transition of classical to intermediate monocytes in a p38 MAPK-dependent manner,”
2

Study evidence

In vivo administration of the p38 MAPK inhibitor losmapimod to healthy volunteers recapitulated p38 blockade effects seen in vitro and is reported to block the classical-to-intermediate monocyte transition, resulting in fewer intermediate monocytes.

“and when administering the p38 MAPK inhibitor losmapimod in vivo to healthy volunteers.”
Claim 4 of 7Not coveredIn healthy volunteers, a tiny injection of UV-killed E. coli triggered a temporary inflammatory response with pain, redness, heat, and swelling.View evidenceHide evidence

As stated24 volunteers total; 12 treated and 12 placebo in each arm

Why this verdict

The abstract-level profile supports that intradermal UV-killed E. coli was used in healthy volunteers as an acute resolving inflammation model and that pain and local inflammatory signs such as heat, redness, and swelling were assessed. However, the stated volunteer counts and allocation details are not available in the abstract-level profile, and the exact characterization as a 'tiny' injection is also not verifiable at this depth.

1

Study evidence

Epoxy‑oxylipins are detectable in peripheral blood at baseline and following intradermal UV‑killed E. coli challenge in healthy male volunteers.

“epoxy-oxylipins are present in blood of healthy, male volunteers at baseline and following intradermal injection of UV-killed Escherichia coli, an experimental model of acute resolving inflammation.”
2

Study evidence

Administration of the selective sEH inhibitor GSK2256294 specifically elevates circulating epoxy-oxylipins 12,13-EpOME and 14,15-EET.

“GSK2256294, a selective sEH inhibitor specifically elevates 12,13-EpOME and 14,15-EET.”
Claim 5 of 7Not coveredThe authors frame the findings as a potential route to safer anti-inflammatory treatments and possible clinical trials for chronic inflammatory conditions such as rheumatoid arthritis and cardiovascular disease.View evidenceHide evidence

Why this verdict

The abstract-level profile does not provide author discussion about safer anti-inflammatory treatments, clinical trials, rheumatoid arthritis, or cardiovascular disease. The profile does support biological relevance to inflammation resolution, but disease-specific translational framing and safety claims are not verifiable from the supplied abstract-depth evidence.

Claim 6 of 7SupportedThe new study, published in Nature Communications, points to epoxy-oxylipins as part of the inflammation shutdown process.View evidenceHide evidence

Why this verdict

This is appropriately hedged. The abstract-level profile reports dynamic regulation and increased biosynthesis of epoxy-oxylipins during human experimental inflammation, pharmacodynamic elevation of 12,13-EpOME and 14,15-EET with sEH inhibition, and mechanistic evidence implicating 12,13-EpOME in monocyte-transition control.

1

Study evidence

Epoxy‑oxylipins are detectable in peripheral blood at baseline and following intradermal UV‑killed E. coli challenge in healthy male volunteers.

“epoxy-oxylipins are present in blood of healthy, male volunteers at baseline and following intradermal injection of UV-killed Escherichia coli, an experimental model of acute resolving inflammation.”
2

Study evidence

Administration of the selective sEH inhibitor GSK2256294 specifically elevates circulating epoxy-oxylipins 12,13-EpOME and 14,15-EET.

“GSK2256294, a selective sEH inhibitor specifically elevates 12,13-EpOME and 14,15-EET.”
Claim 7 of 7SupportedThe treatment did not significantly change outward signs such as redness or swelling.View evidenceHide evidence

Why this verdict

The abstract-level profile explicitly states that sEH inhibition hastened pain resolution but had no effect on local tissue heat, redness, or swelling, matching the story’s claim about outward signs.

1

Study evidence

Administration of the selective sEH inhibitor GSK2256294 specifically elevates circulating epoxy-oxylipins 12,13-EpOME and 14,15-EET.

“GSK2256294, a selective sEH inhibitor specifically elevates 12,13-EpOME and 14,15-EET.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • At the inflammatory site, fewer intermediate monocytes are accompanied by reduced tissue CD4 T cells.

    The story mentions reduced intermediate monocytes in tissue but does not report the associated reduction in tissue CD4 T cells, which is a material secondary immune finding in the profile.

    From inflammatory-site immune profiling

7 things the story did carry across
  • Human experimental inflammation model: intradermal UV-killed E. coli in healthy volunteers to induce acute resolving inflammation.
  • Epoxy-oxylipins and their metabolic machinery are dynamically regulated during the inflammatory response, including increased local biosynthesis at the inflammatory site.
  • GSK2256294 selectively elevates epoxy-oxylipins, notably 12,13-EpOME and 14,15-EET.
  • sEH inhibition hastens pain resolution but does not affect local heat, redness, or swelling.
  • GSK2256294 significantly reduces circulating intermediate monocytes during experimentally induced inflammation.
  • 12,13-EpOME blocks classical-to-intermediate monocyte transition via a p38 MAPK-dependent mechanism, supported by in vitro p38 blockade and in vivo losmapimod dosing.
  • Translation to chronic inflammatory diseases or clinical treatment remains unproven in the abstract-level profile.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

6

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroEstablish a mechanistic link whereby 12,13-EpOME blocks classical-to-intermediate monocyte transition via p38 MAPK, supported by in vitro p38 inhibition and in vivo p38 inhibitor (losmapimod) dosing in humans.in vitro primary human monocyte differentiation assay with lipid treatment and p38 inhibitionExpand

In plain English

In primary human monocyte culture assays, treatment with the epoxy-oxylipin 12,13-EpOME inhibited the phenotypic transition from classical to intermediate monocytes; this inhibitory effect required p38 MAPK signalling, as pathway blockade recapitulated the effect in vitro.

Key findings

  • 12,13-EpOME inhibits the transition of classical to intermediate monocytes in primary human monocyte culture; this effect is dependent on p38 MAPK signalling and is recapitulated by pharmacologic p38 MAPK blockade in vitro.
“12,13-EpOME blocks the transition of classical to intermediate monocytes in a p38 MAPK-dependent manner,”
What this piece can’t prove

2 further details could not be confirmed from the summary.

2human in vivoMap the presence and dynamic regulation of epoxy-oxylipins and their metabolic machinery (CYP450s and epoxide hydrolases) in a human experimental model of acute resolving inflammation.human experimental inflammation time-courseExpand

In plain English

In a human experimental acute resolving inflammation model (intradermal UV‑killed E. coli in healthy male volunteers), epoxy‑oxylipins were detected in blood at baseline and after challenge; at the tissue site of inflammation, CYP450 and epoxide hydrolase (EH) isoforms showed differential upregulation across the response and biosynthesis of epoxy‑oxylipins was increased, indicating dynamic, site‑specific regulation of oxylipin metabolic pathways during the time course of inflammation.

Key findings

  • Epoxy‑oxylipins are detectable in peripheral blood at baseline and following intradermal UV‑killed E. coli challenge in healthy male volunteers.
  • At the site of inflammation, CYP450s and epoxide hydrolase isoforms are differentially upregulated over the inflammatory response, accompanied by increased biosynthesis of epoxy‑oxylipins.
“epoxy-oxylipins are present in blood of healthy, male volunteers at baseline and following intradermal injection of UV-killed Escherichia coli, an experimental model of acute resolving inflammation.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

3human in vivoTest whether selective soluble epoxide hydrolase (sEH) inhibition (GSK2256294) modulates clinical resolution and circulating/site immune-cell dynamics in human inflammation.Human interventional experimental inflammation with selective sEH inhibitorExpand

In plain English

In a human experimental inflammation model (intradermal UV‑killed E. coli) in healthy male volunteers, administration of the selective soluble epoxide hydrolase (sEH) inhibitor GSK2256294 selectively increased circulating epoxy-oxylipins (notably 12,13-EpOME and 14,15-EET), accelerated resolution of pain but did not alter local heat, redness or swelling, and reduced the expansion of circulating intermediate monocytes during inflammation. Mechanistic data indicate 12,13-EpOME blocks the transition from classical to intermediate monocytes via a p38 MAPK-dependent mechanism; this effect was recapitulated by p38 MAPK blockade in vitro and by the p38 inhibitor losmapimod in vivo. Fewer intermediate monocytes and reduced tissue CD4 T cells were observed at the site of inflammation. The study mapped expression and activity of cytochrome P450s and epoxide hydrolase isoforms and the biosynthesis of epoxy-oxylipins across the inflammatory response.

Key findings

  • Administration of the selective sEH inhibitor GSK2256294 specifically elevates circulating epoxy-oxylipins 12,13-EpOME and 14,15-EET.
  • sEH inhibition with GSK2256294 hastens resolution of pain but has no effect on local tissue heat, redness, or swelling.
“GSK2256294, a selective sEH inhibitor specifically elevates 12,13-EpOME and 14,15-EET.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

4human in vivoTest whether selective soluble epoxide hydrolase (sEH) inhibition (GSK2256294) modulates clinical resolution and circulating/site immune-cell dynamics in human inflammation.human interventional (experimental skin inflammation with pharmacological perturbation)Expand

In plain English

In an experimental human model of acute resolving inflammation, selective inhibition of soluble epoxide hydrolase (GSK2256294) was associated with a significant reduction in the numbers of circulating intermediate monocytes that expand during the inflammatory response.

Key findings

  • GSK2256294 significantly reduces numbers of circulating intermediate monocytes that expand during experimentally induced inflammation.Significant reduction reported (no numeric magnitude provided in abstract)
“GSK2256294… significantly reduces numbers of circulating intermediate monocytes that expand during inflammation.”
What this piece can’t prove
  • Sex-limited reporting in abstract (healthy, male volunteers) limits generalizability.

2 further details could not be confirmed from the summary.

5human in vivoEstablish a mechanistic link whereby 12,13-EpOME blocks classical-to-intermediate monocyte transition via p38 MAPK, supported by in vitro p38 inhibition and in vivo p38 inhibitor (losmapimod) dosing in humans.Expand

In plain English

The paper reports that administering the p38 MAPK inhibitor losmapimod to healthy volunteers in vivo recapitulated the effect of p38 blockade observed in vitro, supporting a mechanism whereby 12,13-EpOME blocks classical-to-intermediate monocyte transition via p38 MAPK; this intervention was associated with reduced numbers of intermediate monocytes in the human inflammatory setting.

Key findings

  • In vivo administration of the p38 MAPK inhibitor losmapimod to healthy volunteers recapitulated p38 blockade effects seen in vitro and is reported to block the classical-to-intermediate monocyte transition, resulting in fewer intermediate monocytes.
“and when administering the p38 MAPK inhibitor losmapimod in vivo to healthy volunteers.”
What this piece can’t prove
  • It is not specified whether the losmapimod intervention was part of a randomized comparison or a single-arm perturbation within the study.

2 further details could not be confirmed from the summary.

6human in vivoConnect altered intermediate monocyte biology at the inflammatory site with changes in local adaptive immunity (reduced tissue CD4 T cells).inflammatory-site immune profilingExpand

In plain English

In the human acute resolving inflammation model, the authors report that at the inflammatory site there are fewer intermediate monocytes, and this local reduction is accompanied by reduced numbers of tissue CD4 T cells.

Key findings

  • At the inflammatory site there are fewer intermediate monocytes, and this is accompanied by reduced tissue CD4 T cells.
“Furthermore, fewer intermediate monocytes are observed at the site of inflammation, accompanied by reduced tissue CD4 T cells.”
What this piece can’t prove
  • Unclear whether site-level observations reflect baseline, post-challenge, or post-intervention timepoints and which interventions (if any) drove the changes.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 38 candidate papers

And 32 more candidates considered.